{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:58:14Z","timestamp":1785308294440,"version":"3.55.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant therapy has become a cornerstone of curative-intent management for resectable non-small cell lung cancer (NSCLC), particularly since immune checkpoint inhibitors and biomarker-guided strategies entered perioperative practice. However, the field\u2019s global knowledge structure, collaboration architecture, and surgery-relevant thematic transitions have not been comprehensively mapped.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publications on neoadjuvant\/induction\/preoperative therapy and surgery for NSCLC (January 1989 to September 2025) were retrieved from the Web of Science Core Collection, PubMed, and Wanfang. Bibliometrix, VOSviewer, and CiteSpace were used to quantify productivity and impact, map collaboration and coupling networks, and identify co-citation clusters and citation\/keyword bursts. Latent Dirichlet Allocation (LDA; k=8) was applied to abstracts and keywords to characterize semantic domains and their evolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,512 publications were included. China and the United States were the dominant contributors and citation hubs. European countries showed higher proportions of multinational collaborations. Core journals formed a dual source landscape bridging thoracic surgery and oncology\/immunology. Co-citation clustering showed strong structural validity and highlighted the rise of neoadjuvant chemoimmunotherapy, perioperative safety, and pathological response endpoints. LDA confirmed a shift from induction chemotherapy\/chemoradiotherapy toward immunotherapy-centered perioperative paradigms and translational monitoring. Surgery-facing synthesis of representative landmark studies emphasized evolving emphases on complete resection, downstaging, and lung-sparing operative strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>From January 1989 to September 2025, neoadjuvant NSCLC research transitioned from cytotoxic induction to immunologically driven, biomarker-informed perioperative paradigms tightly integrated with surgery. This integrated bibliometric\u2013semantic framework provides a reproducible approach to monitor emerging fronts and to translate research signals into clinically interpretable questions for multidisciplinary perioperative decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1900455","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:21Z","timestamp":1785304701000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global research trends and thematic evolution in neoadjuvant therapy and surgery for non-small cell lung cancer: a bibliometric and scientometric analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinyu","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Oncology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fifth Hospital of Wuhan","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedong","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Renmin Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca-A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk093","article-title":"Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer","volume":"99","author":"van Meerbeeck","year":"2007","journal-title":"Jnci-Journal Natl Cancer Institute"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain","year":"2009","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"100082","DOI":"10.70389\/PJS.100082","article-title":"TITAN guideline checklist 2025: standards for transparent reporting of analytical research","year":"2025"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.32614\/cran.package.bibliometrix","article-title":"bibliometrix: An R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetrics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/0003-4975(94)92195-4","article-title":"Neoadjuvant therapy - a novel and effective treatment for stage IIIB nonsmall cell lung-cancer","volume":"58","author":"Rusch","year":"1994","journal-title":"Ann Thorac Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050090","article-title":"Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment","volume":"123","author":"Junker","year":"1997","journal-title":"J Cancer Res Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.5.1584","article-title":"Grading of tumor regression in non-small cell lung cancer - morphology and prognosis","volume":"120","author":"Junker","year":"2001","journal-title":"Chest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejcts.2007.01.075","article-title":"ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer","volume":"32","author":"De Leyn","year":"2007","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.095","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21417\/tc2020nm","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00075","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2023.10.052","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00551-9","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00127204","article-title":"Morbidity and mortality in the surgery arm of EORTC 08941 trial","volume":"26","author":"Van Schil","year":"2005","journal-title":"Eur Respir J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.8015","article-title":"Alectinib as neoadjuvant treatment in potentially resectable stage III ALK-positive NSCLC: final analysis of ALNEO phase II trial (GOIRC-01-2020-ML42316)","volume":"43","author":"Leonetti","year":"2025","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0043","article-title":"NCCN guidelines(R) insights: non-small cell lung cancer, version 7.2025","volume":"23","author":"Riely","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2007.01.075","article-title":"Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines","volume":"3","author":"De Leyn","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2006.08.008","article-title":"ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer","volume":"30","author":"Lardinois","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2022.01.019","article-title":"Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer","volume":"164","author":"Sepesi","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2023.09.073","article-title":"Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer","volume":"167","author":"Feldman","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14280","article-title":"Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung","volume":"13","author":"Feng","year":"2022","journal-title":"Thorac Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13045-022-01355-8","article-title":"Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1515\/jtim-2025-0052","article-title":"A signature of plasma exosomal miRNAs predict therapeutic efficacy to neoadjuvant immunotherapy in patients with non-small cell lung cancer","volume":"13","author":"Zhai","year":"2025","journal-title":"J Trans Internal Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1515\/jtim-2025-0047","article-title":"Protocol for Chinese lung cancer evolution and microenvironment tracking under therapy study","volume":"13","author":"Wang","year":"2025","journal-title":"J Trans Internal Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1634\/theoncologist.2018-0120","article-title":"Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study","volume":"24","author":"Xiong","year":"2019","journal-title":"Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","article-title":"Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non-Small Cell Lung Cancer: The TD-FOREKNOW Randomized Clinical Trial","volume":"9","author":"Lei","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:23Z","timestamp":1785304703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1900455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2026.1900455"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1900455","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1900455"}}